Because aberrations in the PI3K/AKT/mTORC1 pathway are common in PDAC and TNBC [55, 56], it is likely that hyperactivated mTORC1 in these cancers upregulates ERO1α expression and then promotes tumor progression. This evidence concerns the gene ERO1A and cancer.